Mutation induction at the hypoxanthine-guanine phosphoribosyl transferase (hprt) locus has been studied in three human bladder tumour cell lines of varying radiosensitivity. U1-S40b, a radiosensitive mutant clone of MGH-U1, has been previously reported to show no difference in split-dose recovery or low dose-rate sparing, but to have an impaired repair fidelity when compared to its parent line. In this paper we have shown that U1-S40b is less mutable at the hprt locus at a similar level of survival. This may represent an increased incidence of severe or non-repairable lesions, making hprt- mutants poorly recoverable in U1-S40b when compared to MGH-U1. No difference was seen in mutation induction between MGH-U1 and RT112, another human bladder tumour cell line of similar radiosensitivity to MGH-U1.. ...
Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).: The study was initiated as an in vitro appr
TY - JOUR. T1 - Antigen common to several species, recognized by a rat monoclonal antibody raised against syngeneic rat bladder tumor. AU - Eto, Hiroshi. AU - Saya, Hideyuki. AU - Nakata, Motomi. AU - Mizoguchi, Akira. AU - Kamidono, Sadao. PY - 1989/9/15. Y1 - 1989/9/15. N2 - A rat monoclonal antibody (MAb) termed RS‐11 (Ig M) was obtained by syngeneic immunization with rat bladder tumor cells induced by N‐butyl, N‐hydroxybutylnitrosamine (BBN). immunocytochemical analysis showed that RS‐11 is also reactive with mouse, dog and human bladder tumor‐cell lines and some other human tumor‐cell lines but not myeloma or leukemia cells. Immunohistochemical examination of paraffin‐embedded tissues has shown that RS‐11 is reactive with mouse, rat, dog and human bladder tumors (5/5, 5/5, 1/1, 31/ 49) and some other tumors, but not with normal human uro‐thelium or normal rat tissues. The antigen is expressed on the majority of low‐grade or well‐differentiated tumors, but less on ...
Bladder cancer is the fifth most common cancer in the United States with an estimated 71,000 new cases and approximately 14,000 deaths in 2009. Bladder cancer is also the costliest to treat per patient of all cancers, with annual direct medical expenditures in excess of $3.7 billion in the United States. This is largely because approximately 70% of all new cases of bladder cancer present as non-muscle invasive bladder cancer (NMIBC), which tends to recur, requiring repeated interventions and long-term follow-up.. NMIBC tumors are usually treated by surgical resection and intravesical chemotherapy and immunotherapy. Immunotherapy usually consists of intravesical administration of Bacillus Calmette-Guerin (BCG). Recent studies suggest that BCG is superior in terms of efficacy and decreasing disease recurrence compared to other therapies. Although the mechanism of action for BCG therapy leading to clinical efficacy is unclear, macrophages, T lymphocytes and natural killer (NK) cells are implicated ...
PURPOSE: Despite over 70,000 new cases of bladder cancer in the United States annually, patients with advanced disease have a poor prognosis due to limited treatment modalities. We evaluate the role of Aurora A, identified as an upregulated candidate molecule in bladder cancer, in regulating bladder tumor growth. EXPERIMENTAL DESIGN: Gene expression in human bladder cancer samples was evaluated using RNA microarray and reverse-transcriptase PCR. The specific Aurora kinase A inhibitor MLN8237 (Millennium) was used to determine effects on bladder cancer cell growth using in vitro and in vivo models using malignant T24 and UM-UC-3 and papilloma-derived RT4 bladder cells. RESULTS: Urothelial carcinoma upregulates a set of 13 mitotic spindle associated transcripts, as compared to normal urothelium, including MAD2L1 (7.6-fold), BUB1B (8.8-fold), Aurora kinases A (5.6-fold) and Aurora kinase B (6.2-fold). Application of MLN8237 (10nM-1µM) to the human bladder tumor cell lines T24 and UM-UC-3 induced dose
In the United States, urothelial carcinoma (UC) of the bladder is the fourth most common malignancy in men and ninth most common in women with 72,570 new cases and 15,210 deaths expected in 2013. Bladder cancer can be divided into low-grade and high-grade tumors. While patients with low-grade tumors uniformly have a good prognosis, those with high-grade tumors clinical outcome is much worse and much more varied (so called heterogeneous). To better understand the heterogeneity within high-grade bladder cancer we examined the expression patterns of genes within a large group of high-grade, muscle-invasive bladder tumors and found that there are two distinct classes of bladder tumors that can be distinguished by their gene expression patterns but not by other means such as histology. Because of their similarity to several of the expression subtypes of breast cancer we have named the "basal" and "luminal" and developed a gene expression classifier consisting of 47 genes (BASE47) that can accurately ...
Pathology of Bladder Cancers, stages of bladder cancer, non-muscle invasive bladder cancer (NMIBC), personalized therapy for NMIBC, expected side effects of TURBT, costs involved for the management of bladder cancer.
Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial.
Approximately 70 percent of new urothelial (formerly called transitional cell) bladder cancer cases are classified as non-muscle invasive. Non-muscle invasive bladder cancer includes Ta, T1 (submucosal invasive) tumors, and Tis (carcinoma in situ [CI
Horvath, A, Simpson, GR, Coffin, RS, Mostafid, H and Pandha, H (2009) NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER: COMBINATION OF A FUSOGENIC GLYCOPROTEIN, PRO-DRUG ACTIVATION AND ONCOLYTIC HERPES SIMPLEX VIRUS ...
Purpose To monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe). Participants The SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in ...
TY - JOUR. T1 - BCG Immunotherapy Against Non-Muscle Invasive Bladder Cancer. T2 - Recent Results, Current Studies and Future Perspectives. AU - Takeuchi, Ario. AU - Shiota, Masaki. AU - Tatsugami, Katsunori. AU - Yokomizo, Akira. AU - Eto, Masatoshi. PY - 2016/1/1. Y1 - 2016/1/1. UR - http://www.scopus.com/inward/record.url?scp=84979097020&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84979097020&partnerID=8YFLogxK. M3 - Review article. C2 - 27333654. AN - SCOPUS:84979097020. VL - 107. SP - 8. EP - 11. JO - Fukuoka Acta Medica. JF - Fukuoka Acta Medica. SN - 0016-254X. IS - 1. ER - ...
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isnt fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive (NMI) bladder cancer eventually become the more dangerous, muscle-invasive (MI) form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?. A University of Colorado Cancer Center study published today in the journal Stem Cells shows its the latter: the progenitor cells that create MI bladder cancer are different than the progenitor cells that create NMI bladder cancer. Though these two cancers grow at the same site, they are different diseases.. "This work provides an important new perspective on how we look at bladder cancer biology," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center and the studys senior author.. The group including first author Garrett Dancik, PhD, ...
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 combined with gemcitabine for patients who have BCG failure (defined as refractory, relapsing or intolerant), non-muscle invasive bladder cancer and refuse or are not medically fit to undergo a radical cystectomy recommended by the participating urologist as the standard next therapy per urologic guidelines. The purpose of this study is to confirm the safety and tolerability of a well-tolerated dose level of ALT-801, to determine the Recommended Dose level (RD) and characterize the immunogenicity of ALT-801 combined with gemcitabine in treated patients. The anti-tumor responses will also be assessed ...
... (MIBC) is a cancer that spreads into the detrusor muscle of the bladder. The detrusor muscle is the thick muscle deep in the bladder wall. This cancer is more likely to spread to other parts of the body. About 1 out of 4 people who get bladder cancer in the United States have the muscle invasive kind.
The Food and Drug Administration approved Keytruda for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer.|br /|  
Combined gemcitabine and cisplatin (GC) treatment is a first line chemotherapy for bladder cancer. However, acquired resistance to GC has been a major problem. To address the mechanism of gemcitabine resistance, and to identify potential biomarkers or target proteins for its therapy, we aimed to identify candidate proteins associated with gemcitabine resistance using proteomic analysis. We established gemcitabine‑resistant human bladder cancer cell lines (UMUC3GR and HT1376GR) from gemcitabine‑sensitive human bladder cancer cell lines (UMUC3 and HT1376). We compared the protein expression of parental and gemcitabine‑resistant cell lines using isobaric tags for relative and absolute quantification (iTRAQ) and liquid chromatography tandem mass spectrometry. Among the identified proteins, ethylmalonyl‑CoA decarboxylase (ECHDC1) expression was significantly increased in both of the gemcitabine‑resistant cell lines compared to the respective parental cell lines. Silencing of ECHDC1 reduced ...
DiseaseFix brings interesting disease graphics, videos, pictures, photos, and images on Bladder Neoplasm. Watch graphics along with explanatory content at one place for Bladder Neoplasm. Causes, Symptoms, Diagnosis, Treatment.
Few studies have demonstrated gene/environment interactions in cancer research. Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P-interaction ,= .001), rs11892031 (UGT1A, P-interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P-interaction = .03). There was limited evidence for multiplicative interactions. When we examined detailed data on a prevalent occupational exposure associated with increased bladder cancer risk, straight metalworking fluids, we also observed statistically significant additive interaction for rs798766 (TMEM129-TACC3-FGFR3, P-interaction = .02), with the interaction more apparent in patients with tumors positive for FGFR3 expression. All statistical tests were two-sided. The interaction ...
In this work we have used Fourier transform infrared (FTIR) / vibrational absorption (VA) spectroscopy to study two cancer cell lines: the Henrietta Lacks (HeLa) human cervix carcinoma and 5637 human bladder carcinoma cell lines. Our goal is to experimentally investigate biochemical changes and differences in these cells lines utilizing FTIR spectroscopy. We have used the chemometrical and statistical method principal component analysis (PCA) to investigate the spectral differences. We have been able to identify certain bands in the spectra which are so-called biomarkers for two types of cell lines, three groups for the 5637 human bladder carcinoma cell line (5637A, 5637B and 5637C), and another one for the HeLa human cervix carcinoma cell line. The vibrational modes can be assigned to specific bands involving characteristic motions of the protein backbone. This work shows that infrared vibrational absorption (VA) spectroscopy can be used as a useful tool in medical diagnostics that provides in ...
Publications, guidelines and educational videos on Non Muscle Invasive Bladder Cancer (NMIBC). Open access. Content provided by Elsevier.
There are limited established therapies for bladder cancer, which can be lethal if it reaches advanced stages and invades surrounding muscle tissue. Segovia, San José-Enériz, Munera-Maravilla, and colleagues found that expression of the histone methyltransferase G9a, suggested in prior studies to be a bladder cancer oncoprotein, was higher in human non-muscle-invasive bladder cancer tumors than in adjacent healthy tissue, and higher levels of the G9a mRNA and protein were correlated with increased chance of bladder cancer recurrence. CM-272, a G9a/DNMT inhibitor, inhibited cell proliferation in some bladder cancer cell lines, and cell lines resistant to CM-272 had mutations in PIK3CA. Because G9a and EZH2 coregulate H3K27me3 and activating mutations in PIK3CA reduce EZH2 and H3K27me3 in bladder cancer, CM-272 resistance may be related to EZH2 activity; supporting this, PIK3CA-mutant bladder cancer cells had decreased EZH2 levels, and PIK3CA-mutant bladder cancer cells exhibited EZH2 ...
The wall of the bladder is lined with several layers of cells called transitional cells. Cancer arising from these cells makes up more than 90% of all bladder cancers and these are referred to as transitional cell carcinomas. Because transitional cell carcinomas are the most common type of bladder cancer, the information in this section only addresses treatment of transitional cell cancer of the bladder. Bladder cancer occurs predominantly in elderly men and less frequently in women and younger men. Many bladder cancers are thought to be caused by exposure to cancer-causing agents that pass through the urine and come into contact with the bladder lining. The most important risk factor for bladder cancer is smoking, which increases risk by at least four-fold.[1]. The most common sign of bladder cancer is hematuria or blood in the urine, which will turn the urine rust or red in color.[2] Other signs of bladder cancer may include pain during urination and frequent urination. Most patients with ...
In the present study we demonstrated for the first time that, Pim-1 was increased in human bladder cancer epithelium as compared with that in normal bladder tissue. When the tumors were stratified by Non-invasive and invasive, a statistically significant increase of Pim-1 expression was found in the subgroup of invasive tumor when compared with that in the Non-invasive tumor. Pim-1 was also detected in all human bladder cancer cell lines tested in our study. Knockdown Pim-1 led to decreased phosphorylation of Bad and reduced expression of Bcl-2. Furthermore, downregulation of Pim-1 inhibited the bladder cancer cells growth and sensitized them to chemotherapy in vitro. Further evaluation of the prognostic significance of Pim-1 in a larger cohort with sufficient follow-up times will allow better understand of the clinical significance of Pim-1.. Overexpression of the Pim-1 protein has been reported in hematolymphoid malignancies and solid cancers [4, 5]. Pim-1 has been asserted to promote ...
p,,b,BACKGROUND: ,/b,In the past decade, adjuvant chemotherapy (AC) after radical cystectomy (RC) was preferred worldwide for patients with muscle-invasive urothelial bladder cancer. In this study we aimed to determine the outcome of patients who received AC and evaluated prognostic factors associated with survival.,/p,,p,,b,PATIENTS AND METHODS: ,/b,We retrospectively analyzed 226 consecutive patients treated in 6 academic hospitals between 2000 and 2009. Multivariate Cox proportional hazards regression adjusted for center to estimate adjusted hazard ratios (HRs) with 95% confidence intervals were used.,/p,,p,,b,RESULTS: ,/b,The median age was 62.4 (range, 35-82) years. Patients had pT3/pT4 and/or pN+ in 180 (79.6%) and 168 patients (74.3%), respectively. Median lymph node (LN) density was 25% (range, 3.1-100). Median time between RC and AC was 61.5 (range, 18-162) days. Gemcitabine with cisplatin, gemcitabine with carboplatin, and MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) ...
The hexylester of 5-aminolevulinic acid (HAL) is a very efficient precursor of the photosensitizer protoporphyrin IX (PpIX) for photodynamic therapy (PDT). Our previous study, performed in rat orthotopic bladder tumors, indicated an opposite effect of HAL/PpIX-PDT according to HAL concentration. The present study investigated possible reasons for this differential effect considering the impact of extracted amounts of PpIX in normal and tumor bearing bladders along with PpIX distribution in distinctive histopathological layers. High performance liquid chromatography (HPLC) analysis of tumor and normal bladder tissues after 8 mM and 16 mM HAL instillation showed that PpIX was the main porphyrin species. The PpIX production in tumor bladders instilled with 8 mM HAL was significantly higher than after 16 mM HAL. Fluorescence confocal microscopy demonstrated a punctuate bright fluorescence pattern in tumor zones of bladders instilled with 8 mM HAL, whereas a more diffuse cytoplasmatic fluorescence
View Poster. INTRODUCTION. There has been increasing awareness of the importance of three-dimensional culture of cancer cells. Tumor cells growing as multicellular spheroids (organoids) are believed to more closely mimic solid tumors in situ. Meanwhile, Wnt/β-catenin pathway was reported to be upregulated in human bladder cancer specimens. However, no clear evidence has been reported that the pathway is directly involved in proliferation of bladder cancer cells. In this study, we assessed the involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells using organoid culture.. METHODS. Organoids from bladder cancer cell lines RT4 (luminal phenotype) and 5637 (basal phenotype) were generated by an aggregation method. A partial-digestion method was applied to prepare organoids directly from patient bladder cancer specimens. Wnt/β-catenin pathway was activated by using a small molecule CHIR99021 (GSK3 inhibitor, Wnt activator) and inhibited by siRNA against β-catenin. ...
U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT03081858) titled Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer on March 10. Brief Summary: This is a single-arm, phase 1/2a study of formulated paclitaxel in subjects with low-grade, noninvasive papillary carcinoma (stage Ta) of the bladder. Part 1 of the study will enroll 6 subjects (3 per cohort) with low-grade, stage Ta transitional cell carcinoma (TCC) of the bladder who will receive escalating doses of paclitaxel formulated as TSD-001 every 2 weeks for 6 treatments until Dose Limiting Toxicity (or until the Maximum Deliverable Dose) is observed (Maximum Tolerated Dose established). Part 2 of the study will enroll an additional 10 subjects with low-grade, stage Ta (multifocal) TCC of the bladder who will receive weekly TSD-001 for 6 weeks at the highest nontoxic dose (i.e., MTD) established in part 1 of the study. Study Start Date: ...
Several lymphangiogenic factors, such as vascular endothelial growth factors (VEGFs), have been found to drive the development of lymphatic metastasis in bladder cancer (BCa).Here, we have analyzed the gene expression of lymphangiogenic factors in tissue specimens from 12 non-muscle invasive bladder cancers (NMIBC) and 11 muscle invasive bladder cancers (MIBC), considering tumor and tumor-adjacent normal bladder areas obtained from the same organs. We then compared the results observed in patients with those obtained after treating human primary bladder microvascular endothelial cells (MEC) with either direct stimulation with VEGF-A or VEGF-C or by co-culturing (trans-well assay) MEC with bladder cancer cell lines varying in VEGF-A and VEGF-C production based on tumor grade ...
Urinary bladder cancer in cats is characterized by an abnormal growth of cells within the urinary bladder. The most common type urinary bladder cancer seen in cats is rooted from a tumor called transitional cell carcinoma (TCC).
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Human Bladder Tumor lysate \ HTL-1325 for more molecular products just contact us
We have investigated the effects of tumor necrosis factor-alpha (TNF-alpha) and interferon (INF-gamma), the potent Bacillus Calmette-Guerin (BCG)-induced cytokines on the production of MMP-2, MMP-9, TIMP-1, TIMP-2 and MT1-MMP in high grade human bladder cancer cell lines, T-24, J-82 and HT-1376 cell lines. MMP-2 expression and activity were decreased in T-24 cells treated with both cytokines in a dose dependent manner. However, J-82 cells treated with TNF-alpha and INF-gamma revealed dose dependent increases of MMP-9 expression and activity with similar baseline expression and activity of MMP-2. HT-1376 cells after exposure to TNF-alpha only enhanced the expression and activity of MMP-9. These results indicate that TNF-alpha and INF-gamma could regulate the production of MMP-2 or MMP-9 on bladder cancer cells and their patterns of regulation are cell specific. Furthermore, this diverse response of bladder cancer cells to TNF-alpha and INF-gamma suggests that BCG immunotherapy may enhance the
Dr. Mamtani is a medical oncologist and cancer epidemiologist. His clinical practice focuses on bladder cancer and he participates in Penns multidisciplinary bladder cancer clinic. His research sits at the interface between population-science and patient-oriented research and focuses on understanding the role of host factors on bladder cancer outcome.. Dr. Mamtani currently leads an NCI funded prospective cohort study which aims to identify metabolic risk factors for bladder cancer recurrence after cystectomy. He has particular experience using big data from large electronic medical record and administrative databases such as The U.K Health Improvement Network, the U.S. National Cancer Database, Medicare and Medicaid, and Kaiser Permanente of ...
This is a clinical practice guideline on the appropriate use of immunotherapy for the treatment of patients with bladder cancer, specifically non-muscle invasive bladder cancer, muscle invasive bladder cancer, and advanced bladder cancer. The guideline addresses issues related to the definition of risk categories, patient selection, toxicity management, clinical endpoints, as well as the combination and sequencing of therapies. The guideline also highlights areas for future direction and development to advance the use of immunotherapy in bladder cancer treatment.. ...
Currently computed tomography (CT) represents the most widely used standard imaging modality in muscle-invasive urinary bladder cancer. Visualization of local tumor or depth of invasion as well as lymph node staging, however, is often impaired. Magnetic resonance imaging (MRI) with diffusion-weighted sequences, determination of apparent diffusion coefficient (ADC) values or utilization of superparamagnetic iron nanoparticles potentially exhibits advantages in the assessment of local tumor or lymph node involvement and therefore might play a role in routine staging of urinary bladder cancer in the future. Likewise, positron emission tomography (PET) with the currently utilized tracers 18F-FDG, 11C-choline and 11C-acetate is investigated in bladder cancer patients-mostly in combination with diagnostic CT. Although promising results could be obtained for these PET/CT examinations in smaller series, their true value cannot be determined at present.
Recent studies have demonstrated the role of systemic inflammation in the development and progression of cancer. In this study, we evaluated whether preoperatively measured neutrophil-to-lymphocyte ratio (NLR) can predict lamina propria invasion in patients with non-muscle-invasive bladder cancer (NMIBC).
As reported by Rebouissou and colleagues in Science Translational Medicine, a subset of muscle-invasive bladder cancers that present with a basal-like phenotype is associated with poorer survival, EGFR pathway activation, and sensitivity to EGFR inhibition.. Assessment of data from 383 tumors revealed that 23.5% displayed a basal-like phenotype characterized by expression of epithelial basal cell markers and shorter survival. These basal-like tumors exhibited activation of the EGFR pathway associated with frequent EGFR gains and activation of an EGFR autocrine loop. The tumor cells were found to be sensitive to anti-EGFR therapy using both a 40-gene expression classifier derived from human tumors to identify bladder cancer cell lines and a mouse model of chemically induced bladder cancer corresponding to human basal-like bladder cancer.. The authors concluded, "Our findings provide preclinical proof of concept that anti-EGFR therapy can be used to target a subset of particularly aggressive ...
The present study investigated the clinical significance and biological role of MFN2 in bladder cancer pathogenesis. First, the expression level of MFN2 was revealed to be significantly lower in bladder cancer tissue compared with adjacent non-tumor tissues. Second, MFN2 expression level was identified to be associated with tumor stage, lymph node metastasis and poor prognosis in patients with bladder cancer. Third, silencing of MFN2 promoted bladder cancer proliferation and metastasis via regulation of the Wnt/β-catenin signaling pathway. These results indicated that MFN2 is a candidate tumor suppressor in bladder cancer, and may be exploited as a target for potential clinical treatments for bladder cancer.. MFN2, also termed the hyperplasia suppressor gene, was originally identified in vascular smooth muscle cells from spontaneously hypertensive rats (15). Overexpression of MFN2 induces the formation of mitochondrial networks and may involve a major rearrangement of the coiled coil domains ...
A previous study by our group demonstrated that the expression levels of Notch 1 and Jagged 1 in bladder cancer cells was significantly lower compared with those in normal bladder mucosa, while the expression levels of Notch 1 and Jagged 1 in invasive bladder cancer were higher compared with those in superficial bladder cancer. The present study investigated the effect of the Notch signaling pathway on the drug resistance and invasiveness of bladder cancer cells. It was demonstrated that complete inhibition of the Notch signaling pathway induced significant morphological changes and inhibited cell proliferation and migration ( ...
In this study, we compared the effects of the Src inhibitor dasatinib on the urothelial cancer cell line RT112 and its gemcitabine-resistant sub-line RT112rGEMCI20 in cell culture and in an orthotopic bladder cancer xenograft model in mice.. In cell culture, both cell lines displayed similar growth kinetics. Dasatinib inhibited Src phosphorylation in RT112 and RT112rGEMCI20 cells at low nanomolar concentrations similar to those that had already been described to affect Src phosphorylation [9]. While dasatinib had previously been shown to interfere with the phosphorylation of Akt (Thr308 and Ser473) in squamous cell lung cancer [22], we only detected inhibition of phosphorylation of Akt (Thr308). The reasons for this may be the consequence of cell type-specific differences between the investigated models. Although dasatinib exerted similar effects on Src signaling in RT112 and RT112rGEMCI20 cells, its effects on cell viability differed between the two cell lines. The effective concentrations of ...
Purpose: To investigate the clinical management and outcome of patients with muscle-invasive bladder cancer with clinical lymph node involvement, using longitudinal nationwide population-based data.. Methods: In the Bladder Cancer Data Base Sweden (BladderBaSe), treatment and survival in patients with urinary bladder cancer clinical stage T2-T4 N + M0 diagnosed between 1997 and 2014 was investigated. Patients´ characteristics were studied in relation to TNM classification, curative or palliative treatment, cancer-specific (CSS) and overall survival (OS). Age at diagnosis was categorised as ≤60, 61-70, 71-80 and ,80 years, and time periods were stratified as follows: 1997-2001, 2002-2005, 2006-2010 and 2011-2014.. Results: There were 786 patients (72% males) with a median age of 71 years (interquartile range = 64-79 years). The proportion of patients with high comorbidity increased over time. Despite similar low comorbidity, curative treatment was given to 44% and to 70% of those in older (,70 ...
Abstract. Background: Non-muscle invasive bladder cancer (NMIBC) is associated with high rates of recurrence, resulting in frequent follow-up cystoscopies. We evaluated the use of two point-of-care tests - the nuclear matrix protein 22 (NMP22) and urinary bladder cancer antigen (UBC) Rapid - compared to routine follow-up in patients with a previous history of NMIBC.. Methods: 31 patients with cystoscopy-verified active bladder cancer, and 44 follow-up patients without disease as confirmed by cystoscopy were prospectively enrolled. All urine samples were analyzed by voided urine and bladder washing cytology, NMP22 and UBC rapid test (qualitatively and quantitatively). The best cutoff (highest Youden index; ≥6.7 ng/ml) for the quantitative UBC was determined by receiver operating characteristic curves.. Results: Voided urine and barbotage cytology resulted in a sensitivity of 25.8% and 32.3%, and a specificity of 100% and 100%, while the NMP22 showed a sensitivity and specificity of 12.9% and ...
Smilow Cancer Hospital at Yale-New Haven recently became the only hospital in the state to offer Blue Light Cystoscopy with Cysview, which has been proven to significantly increase the detection of bladder cancer over white-light cystoscopy alone. 20.7% of patients with primary bladder cancer had at least one tumor detected with blue light that was not detected with white light. 27.7% of patients with recurrent bladder cancer had at least one tumor detected with blue light that was not detected with white light, and a seven-month improvement in time to recurrence has been demonstrated. Following diagnosis, the multidisciplinary bladder cancer program offers complete care with specialized pathology, neoadjuvant therapy options, an enhanced recovery after surgery (ERAS) protocol that has been demonstrated to reduce the length of stay and post-surgical complications, and advanced surgical techniques to maintain sexual function and bladder control.. Learn more about Cysview here.. ...
Bladder Cancer Treatment of Alternative Bladder Cancer Alternative Neuro Acupuncture Treatment and Bladder Cancer Herbal Herbs Alternative Medicine Treatment on Bladder Cancer Treatment Medical Center Bladder Cancer Remedies
View Poster. INTRODUCTION. Urinary bladder cancer (UBC) patients at muscle invasive stage have poor clinical outcome, due to high propensity for chemoresistance. Cancer-associated fibroblasts (CAFs), one of the principal constituents of the tumor stroma, play an important role in tumor development. Exosomal microRNAs (miRNAs) are emerging mediators of cancer-host crosstalk with other cells around. However, it is unclear whether CAFs from UBC promote cancer chemoresistance through exosomal miRNAs.. METHODS. We obtained human bladder cancer specimens and adjacent normal tissues from Nanjing Drum Tower Hospital. The bladder cancer specimen used for isolation of stromal fibroblasts was diagnosed as muscle invasive bladder cancer with histological grade II. Bladder cancer cells (T24 and 5637) were treated with the conditional medium (CM) or exosomes from normal fibroblasts (NFs) and CAFs, as well as an equal volume of complete culture medium. Exosomes were isolated from NF-CM or CAF-CM using ...
Treatment of recurrent bladder cancer depends mainly on where the cancer recurs and past treatment. Learn about treatment of local or metastatic recurrence.
Contexto. El cáncer vesical no músculo infiltrante de alto riesgo es una enfermedad que integra un grupo heterogéneo de pacientes, en los que se recomienda un seguimiento estrecho debido al riesgo de progresión a tumor músculo infiltrante. El tratamiento de elección de estos tumores es la resección transuretral de vejiga seguido de un programa de instilaciones con BCG. Existe un subgrupo de pacientes que tiene un mayor riesgo de progresión, y que se benefician de un tratamiento radical de inicio.. Objetivo. Identificar qué grupo de pacientes con cáncer vesical no músculo infiltrante se benefician de un tratamiento radical precoz.. Búsqueda de la evidencia. Se realizó una revisión bibliográfica para identificar los factores de riesgo de progresión de estos pacientes, y así poder recomendar un tratamiento que mejore su tasa de supervivencia.. Síntesis de la evidencia. Se identificaron los diferentes factores pronósticos asociados a progresión tumoral: la persistencia de tumor ...
A superficial bladder cancer is a noninvasive cancer that is presented as a good prognosis after receiving treatment, and noninvasive. However, about 20∼50% of superficial bladder cancer patients progressed to invasive tumor which represent the poor survival rates within 5 years. In previous study, we addressed if the transcriptional characteristics of the superficial bladder cancer could be used as predictive biomarkers for the progression of superficial tumors to invasive ones. Using gene expression data from 165 bladder cancer patients, we identified a gene expression signature that could predict the likelihood of progression to invasive tumors. Gene network analyses of the signature revealed that E2F1 and its downstream effectors EZH2 and SUZ12 could be important mediators for the invasive and metastatic progression of superficial tumors. In this study, we investigated how these genes may affect the invasive and metastatic progression of superficial tumors. We investigated the invasive ...
Previously, we have demonstrated that interleukin-4 receptor α (IL-4Rα) is overexpressed on a variety of human cancers and can serve as target for IL-4 immunotoxin comprised of IL-4 and a mutated Pseudomonas exotoxin. However, its expression and association with grade and clinical stage of bladder cancer has not been studied. IL-4Rα expression was examined in human bladder cancer cell lines, mouse xenografts, and biopsy specimens at mRNA and protein levels by real-time RT-PCR and IHC/ISH techniques. We also examined the effect of IL-4 on proliferation and invasion of bladder carcinoma cell lines. For tissue microarray (TMA) results, we analyzed the precision data using exact binomial proportion with exact two-sided P-values. We used Cochran-Armitage Statistics with exact two-sided P-values to examine the trend analysis of IL-4Rα over grade or stage of the bladder cancer specimens. The influence of age and gender covariates was also analyzed using multiple logistic regression models. IL-4Rα ...
Reliable markers for monitoring bladder tumor therapy are needed to evaluate treatment effectiveness. Thymidine kinase 1 (TK1) is an enzyme involved in DNA synthesis and therefore proliferation-dependent. Serum concentration of TK1 (STK1) correlates with malignancy in various types of cancer, thus reflecting treatment results. This study explores for the first time the use of STK1 concentration, both as a prognostic marker and to monitor the outcome of bladder carcinoma surgery. STK1 in 56 bladder carcinoma patients was measured pre-operatively, and post-operatively at 1 week and 1, 3, and 6 months, using an immune ECL dot blot assay. An anti-TK1 chicken IgY antibody was used to determine STK1 concentrations. Mean pre-operative STK1 of bladder carcinoma patients was significantly higher than that of healthy individuals, with no overlap of individual values. STK1 concentrations increased significantly with tumor stage (I-III) and T-values (T1-T2), but not tumor grade (G1-G4). STK1 gradually ...